GSC
VINC

Ground Swell Capital’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Ground Swell Capital’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-750
Closed -$21K – 150
2022
Q3 		$21K Buy
+750
New +$21.6K 0.06% 85

Other funds holding VINC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ground Swell Capital's VINC Position: Q4 2022 in Review

Ground Swell Capital sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2022, closing a stake of 750 shares — an estimated $21K sold.

Ground Swell Capital first reported a position in VINC in Q3 2022 and held it in 1 quarter. The position peaked at $21K in Q3 2022. 35 funds tracked by Wall St. Rank hold VINC as of Q4 2022.

  • Ground Swell Capital reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ground Swell Capital sold 750 Vincerx Pharma, Inc. Common Stock shares in Q4 2022, an estimated $21K.
  • Ground Swell Capital first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Ground Swell Capital's Vincerx Pharma, Inc. Common Stock position peaked at $21K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2022.

Based on Ground Swell Capital's 13F filing for Q4 2022, filed 14 Feb 2023.